Algert World LLC purchased a brand new stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO – Free Report) through the second quarter, in response to its most up-to-date 13F submitting with the SEC. The institutional investor purchased 41,215 shares of the corporate’s inventory, valued at roughly $249,000.
A number of different hedge funds additionally not too long ago modified their holdings of the corporate. CANADA LIFE ASSURANCE Co bought a brand new place in shares of ALX Oncology through the first quarter valued at roughly $27,000. EntryPoint Capital LLC acquired a brand new place in ALX Oncology within the 1st quarter valued at $32,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in ALX Oncology by 394.8% within the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the corporate’s inventory valued at $39,000 after buying a further 5,200 shares over the last quarter. Hsbc Holdings PLC acquired a brand new stake in shares of ALX Oncology through the second quarter value $63,000. Lastly, China Common Asset Administration Co. Ltd. grew its place in shares of ALX Oncology by 66.4% within the first quarter. China Common Asset Administration Co. Ltd. now owns 9,587 shares of the corporate’s inventory valued at $107,000 after buying a further 3,825 shares through the interval. 97.97% of the inventory is owned by institutional buyers and hedge funds.
ALX Oncology Inventory Efficiency
Shares of ALXO inventory opened at $1.62 on Thursday. The corporate’s fifty day easy shifting common is $2.29 and its 200-day easy shifting common is $7.80. The corporate has a present ratio of 4.39, a fast ratio of 4.39 and a debt-to-equity ratio of 0.06. ALX Oncology Holdings Inc. has a 52 week low of $1.56 and a 52 week excessive of $17.83. The corporate has a market cap of $84.40 million, a PE ratio of -0.44 and a beta of 1.00.
ALX Oncology (NASDAQ:ALXO – Get Free Report) final issued its quarterly earnings knowledge on Thursday, August eighth. The corporate reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.01. As a gaggle, equities analysis analysts anticipate that ALX Oncology Holdings Inc. will submit -3.04 EPS for the present 12 months.
Wall Avenue Analyst Weigh In
A number of equities analysts not too long ago weighed in on the corporate. UBS Group diminished their goal worth on ALX Oncology from $25.00 to $4.00 and set a “purchase” score on the inventory in a analysis report on Friday, August sixteenth. HC Wainwright reiterated a “purchase” score and set a $25.00 worth goal on shares of ALX Oncology in a report on Tuesday, August thirteenth. Stifel Nicolaus restated a “maintain” score and issued a $3.00 goal worth (down from $5.00) on shares of ALX Oncology in a report on Friday, August ninth. Cantor Fitzgerald reaffirmed an “chubby” score on shares of ALX Oncology in a analysis notice on Monday, August twelfth. Lastly, Lifesci Capital lowered shares of ALX Oncology from a “strong-buy” score to a “maintain” score in a report on Wednesday, July thirty first. Two funding analysts have rated the inventory with a maintain score and 5 have assigned a purchase score to the inventory. In accordance with knowledge from MarketBeat, the corporate presently has a consensus score of “Reasonable Purchase” and a median goal worth of $12.20.
Test Out Our Newest Inventory Evaluation on ALXO
ALX Oncology Profile
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology firm, focuses on creating therapies for most cancers sufferers in the USA. The corporate’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in growth as a mix remedy with different anti-cancer brokers, together with ASPEN-06, beneath Part 2 scientific research for treating Gastric/GEJ most cancers; ASPEN-07, beneath Part 1 scientific research for treating urothelial most cancers; and ASPEN-03 and ASPEN-04, each beneath Part 2 scientific research for treating head and neck squamous cell carcinoma.
Featured Tales
Need to see what different hedge funds are holding ALXO? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for ALX Oncology Holdings Inc. (NASDAQ:ALXO – Free Report).
Obtain Information & Rankings for ALX Oncology Each day – Enter your e-mail deal with under to obtain a concise day by day abstract of the newest information and analysts’ rankings for ALX Oncology and associated corporations with MarketBeat.com’s FREE day by day e-mail publication.
